The Maryland-based drug developer Emergent BioSolutions has received a multi-million dollar contract to help with the Zika health crisis.

Emergent received a $22 million federal order to develop an early-stage Zika vaccine, which could be ready for trials by early next year.

“Glad the government can rely on us sufficiently to come to us a second and third time to help them with a health crisis,” said Barbara Solow, Emergent BioSolutions.

The Gaithersburg-based company has been called on several times to help during a global virus outbreak, developing a number of vaccines — including anthrax and Ebola.

Read more

Related Articles